Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rhPTX-2 (PRM-151) for idiopathic pulmonary fibrosis has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• rhPTX-2 (PRM-151) (recombinant human pentraxin-2)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2024-04-18